This latest study builds on research from the ONTARGET trial, which showed that telmisartan was as effective as ramipril at cutting CVD risk and better tolerated (GP, 11 April).
The TRANSCEND study found that telmisartan (80mg daily) cut risk of cardiovascular death in high-risk patients by 13 per cent after 56 months.
Primary Care Cardiovascular Society member Dr Sarah Jarvis said: 'We now have evidence that telmisartan protects against heart attack, stroke and cardiovascular death.'
Lancet Online 2008.
Comment below and tell us what you think